Sagefield Capital’s Avadel Pharmaceuticals AVDL Stock Holding History

Sagefield Capital’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-27,231	Closed	-$587K	–	115
2025 Q4	$587K	Buy	+27,231	New	+$529K	0.05%	100

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Sagefield Capital's AVDL Position: Q1 2026 in Review

Sagefield Capital sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 27,231 shares — an estimated $587K sold.

Sagefield Capital first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $587K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Sagefield Capital reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Sagefield Capital sold 27,231 Avadel Pharmaceuticals shares in Q1 2026, an estimated $587K.
Sagefield Capital first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Sagefield Capital's Avadel Pharmaceuticals position peaked at $587K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Sagefield Capital's 13F filing for Q1 2026, filed 15 May 2026.